News Search Results
Apr 07, 2026, 08:00 ET Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data
More news about: Avai Bio, Inc.
Apr 07, 2026, 08:00 ET Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Apr 07, 2026, 07:00 ET Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
improve patient outcomes for the treatment of obesity."About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Apr 06, 2026, 20:00 ET CGBIO Showcases Comprehensive Medical Device Portfolio at KIMES 2026 Achieves KRW 5.3 Billion in Contract Results
SEOUL, South Korea, April 6, 2026 /PRNewswire/ -- CGBIO (CEO Hyunseung Yu), a biotechnology company specializing in regenerative medicine, announced on the 6th that it participated in the 41st Korea International Medical & Hospital
More news about: CGBIO
Apr 06, 2026, 19:30 ET The Inner Circle acknowledges, Melvin Colón as a Pinnacle Professional Member Inner Circle of Excellence
bringing new medical products to market.Mr. Colón is a licensed chemist with a proven track record of success across the pharmaceutical, biotechnology, including cell and gene therapy, biosimilars, and medical device industries, including combination products. His expertise includes Quality Assurance,
More news about: The Inner Circle
Apr 06, 2026, 13:50 ET Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company focused on the development of oral peptide and protein replacement therapies, in a $10 million private placement led by funds affiliated
More news about: Greenberg Traurig, LLP
Apr 06, 2026, 13:10 ET Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
companies have already crossed key manufacturing thresholds in that transition: Avaí Bio (OTCQB: AVAI), Vericel (NASDAQ: VCEL), Sana Biotechnology (NASDAQ: SANA), Lineage Cell Therapeutics (NYSE-A: LCTX), and Eledon Pharmaceuticals (NASDAQ: ELDN).
More news about: USA News Group
Apr 06, 2026, 10:30 ET Digital Biomarkers Market worth $17.73 billion by 2031 | MarketsandMarkets™
(US).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Apr 06, 2026, 09:20 ET NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI)
More news about: NeuroSense
Apr 06, 2026, 09:15 ET Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
HOUSTON, April 6, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, announced that
More news about: Decoy Therapeutics, Inc
Apr 06, 2026, 09:10 ET Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was recently featured in an
More news about: Anixa Biosciences, Inc.
Apr 06, 2026, 09:08 ET Pan Am Cancer Expands Global Leadership in Personalized Cancer Immunotherapy by Collaboration with Internationally Renowned Cancer Pioneer Dr. Baofa Yu
years the group of Dr. Lopez has provided the best available medical immunotherapy for patients, has well as conducted clinical trials for major biotechnology companies, which in some cases have been the basis for FDA clinical trial approvals1. It is an honor to bring our ImmunoSurgery Technology
More news about: Pan Am Cancer Treatment Centers
Apr 06, 2026, 09:00 ET Connecticut Innovations Partners with Mission BioCapital's 2026 Platinum Program to Accelerate Biotech Startups in Connecticut
(MBC), today announced that applications are open for the 2026 Platinum Program, a global initiative designed to launch and scale high-potential biotechnology startups.
More news about: Connecticut Innovations
Apr 06, 2026, 09:00 ET AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Apr 06, 2026, 07:00 ET Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
focused, customer-facing organization with a scalable operating model. On the R&D side, Scinai Immunotherapeutics is a lean, capital-efficient biotechnology company, better positioned to engage with investors, strategic partners and potential future transactions.By consolidating our CDMO activities
More news about: SCINAI IMMUNOTHERAPEUTICS LTD
Apr 06, 2026, 03:25 ET CS Analytical to Exhibit at Interphex 2026 - Highlighting Expanded Service Offering
cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to package and container testing for the pharmaceutical, biotechnology, and medical device industries. The company is excited to announce that it will be attending and displaying at the 2026 Interphex show taking place
More news about: CS Analytical
Apr 06, 2026, 02:28 ET GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
Proprietary analytical method for precise Factor XI (FXI) measurement published in the Journal of Microbiology and BiotechnologyNovel IgG Blocker eliminates heterophilic antibody interference, ensuring clinical-grade purity and mitigating thromboembolic risks
More news about: GC Biopharma
Apr 05, 2026, 16:51 ET TTW Reveals Top 100 Convention Centers in the World for 2026
increased its exhibition footprint, enabling large-scale, column-free event hosting. The venue supports industries such as technology, healthcare, and biotechnology, attracting global corporations and innovators. With high-speed connectivity, certified sustainability standards, and seamless integration into
More news about: Travel And Tour World
Apr 03, 2026, 23:14 ET INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
[email protected] ALLEGATIONS: ImmunityBio is a biotechnology company that focuses on innovating, developing, and commercializing next-generation immunotherapies. According to the complaint, ImmunityBio's lead
More news about: Robbins Geller Rudman & Dowd LLP
Apr 03, 2026, 22:15 ET IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
[email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 03, 2026, 15:19 ET REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights
purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States.
More news about: Robbins LLP
Apr 03, 2026, 10:02 ET NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today announced that it received two notification letters from the Listing
More news about: NeuroSense
Apr 03, 2026, 08:00 ET OneCyte and Kemp Proteins Announce Strategic Partnership to Accelerate High-Performance Cell Line Development for Next-Generation Biologics
capabilities, will provide a powerful and differentiated solution for our global biopharma customers."About OneCyteOneCyte is a biotechnology company focused on transforming cell line development through high-throughput single-cell technologies. Its proprietary platform enables rapid,
More news about: Kemp Proteins
Apr 02, 2026, 17:43 ET ADLX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Aldeyra Therapeutics, Inc.
acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as "biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases." Pertinent to this action is reproxalap, which
More news about: Robbins LLP
Apr 02, 2026, 16:30 ET TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
LinkedIn to learn more.About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists,
More news about: TriNetX, LLC.